[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344276-105":59,"doc-detail-344276-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","patterns-of-neurological-adverse-events-among-a-retrospective-cohort-of-patients-receiving-immune-checkpoint-inhibitors","Patterns of Neurological Adverse Events among a Retrospective Cohort of Patients Receiving Immune Checkpoint Inhibitors","","Neurological adverse events (NAEs) are uncommon outcomes of immune checkpoint inhibitor (ICI) therapy and remain poorly characterized, limiting clinical planning and management. This retrospective cohort study assessed the frequency, severity, patterning, and timing of NAEs across patients receiving at least one ICI dose from 2011 to 2022 within a health-network registry. Among 3137 patients, 54 NAEs occurred (1.72% any grade; 0.8% grade 3–4). NAEs were predominantly peripheral (57.4%) rather than central (42.6%). Melanoma and renal cell carcinoma showed significant associations with NAEs, and event timing aligned with other immune-related adverse events.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/patterns-of-neurological-adverse-events-among-a-retrospective-cohort-of-patients-receiving-immune-checkpoint-inhibitors/344276/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/patterns-of-neurological-adverse-events-among-a-retrospective-cohort-of-patients-receiving-immune-checkpoint-inhibitors/344276.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the study’s main goal?","Question",{"text":113,"@type":114},"To characterize the frequency, severity, patterning, and timing of neurological adverse events in patients receiving immune checkpoint inhibitors.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How common were neurological adverse events in the cohort?",{"text":118,"@type":114},"Among 3137 patients, 54 neurological adverse events were observed (1.72% any grade and 0.8% grade 3–4).",{"name":120,"@type":111,"acceptedAnswer":121},"Were neurological adverse events more often peripheral or central?",{"text":122,"@type":114},"Most NAEs were peripheral (57.4%), with central NAEs comprising 42.6%.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},344276,1790306336,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Research Article  \nPatterns of neurological adverse events among a retrospective cohort of patients receiving immune checkpoint inhibitors  \nJohn C Hunting*,1, Andrew T Faucheux2, Sarah N Price3, Catherine A Elko1, Alexander Quattlebaum1, Chance Bloomer1, Eric Olson2, William J Petty2 & Thomas W Lycan Jr2  \n1 Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA  \n2 Department of Hematology & Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA  \n3 Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA  \n*Author for correspondence: Tel.: +1 336 713 9800; [jhunting@wakehealth.edu](jhunting@wakehealth.edu)  \nAim: Neurological adverse events (NAEs) are infrequent immune checkpoint inhibitor (ICI) outcomes poorly characterized in extant research, complicating their clinical management. Methods: This study characterized the frequency, severity, patterning and timing of NAEs using a large retrospective registry, including all patients who received at least one dose of an ICI from 2/1/2011–4/7/2022 within our health network. Results: Among 3137 patients, there were 54 NAEs (1.72% any grade; 0.8% grade 3– 4) . Most NAEs were peripheral (57 .4%) versus central (42 .6%) . Melanoma and renal cell carcinoma were significantly associated with NAEs. Conclusion: The incidence of NAEs was rare though higher than many prior case estimates; the timing was consistent with other AEs. NAEs frequently occurred in tumor types known to favor brain metastases.  \nPlain language summary: Immune checkpoint inhibitors are new drugs for cancer. They boost your body’s defenses to fight cancer cells. These drugs can be used alone or with other cancer treatments. Most people are okay with these medicines, but some might have problems in different parts of the body. This can be tricky to figure out. Rarely, there can be issues in the brain or nerves. These side effects are rare, happening in about 2 in every 100 people who use the drugs. They are more common in certain cancers like melanoma and kidney cancer. As doctors learn more about these side effects, they can better predict, treat, and prevent them.  \nFirst draft submitted: 22 October 2023; Accepted for publication: 20 December 2023; Published online:  \n10 January 2024  \nKeywords: brain metastasis • central nervous system • immune checkpoint inhibitors • incidence • melanoma • neurological adverse events • peripheral nervous system • renal cell carcinoma  \nImmune checkpoint inhibitor (ICI) therapies can improve progression-free and overall survival in patients with cancer who otherwise have poor prognoses [1,2] . In2018, over40%ofall patients with cancer were considered eligible for immunotherapy-based treatments [3] . ICIs generally have a more favorable side effect proﬁle than traditional therapies (e.g., chemotherapy), but they are also associated with a broad array of immune-related adverse events (AEs), that can involve any organ and range from mild to fatal. A recent meta-analysis of 125 clinical trials and the registration trials for pembrolizumab found that the majority (60–70%) of patients have at least one adverse event of any grade, though few ( \u003C10%) high grade (i.e., Common Terminology Criteria for Adverse Events [CTCAE] 3–5) [4,5] . Among these adverse events is a heterogeneous group of neurotoxicities categorized as neurological adverse events (NAE), less frequently reported than other immune-related AEs. Although the attribution of adverse events as NAE varies across studies, this broad category often includes common side effects (e.g., some types of fatigue, headaches) and rare ones (e.g., seizure, polyneuropathy, isolated nerve palsies, paresthesia, myasthenia gravis, polyradiculopathy and encephalitis) [6] . Due to their heterogeneity in presentation, timing, and severity, NAE are often challenging to diagnose and, therefore, likely under-reported [7] . In many cases, NAE are ","cbCaibICcSDi3wBr","https://ap.wps.com/l/cbCaibICcSDi3wBr","pdf",2195247,"English","# Aim\n# Methods\n# Results\n# Conclusion\n# Plain language summary\n# Background and rationale","[{\"question\":\"What was the study’s main goal?\",\"answer\":\"To characterize the frequency, severity, patterning, and timing of neurological adverse events in patients receiving immune checkpoint inhibitors.\"},{\"question\":\"How common were neurological adverse events in the cohort?\",\"answer\":\"Among 3137 patients, 54 neurological adverse events were observed (1.72% any grade and 0.8% grade 3–4).\"},{\"question\":\"Were neurological adverse events more often peripheral or central?\",\"answer\":\"Most NAEs were peripheral (57.4%), with central NAEs comprising 42.6%.\"}]","Patterns of Neurological Adverse Events among a Retrospective Cohort of Patients Receiving Immune Checkpoint Inhibitors | PDF",1790053329,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53536919a5f74b17bdb3e04e7cbdc335.webp",983,1329,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1c6bce77f4d569a90a01ff9fea71e54.webp",982,1328,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5a8d56895615d7005f05c3589192ffe.webp",981,1326,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb15cab9144d736b6319a570d65a3e68.webp",980,1325]